Home Transmembrane Transporters Potassium Channel inhibitor Mitiglinide Calcium

research use only

Mitiglinide Calcium Potassium Channel inhibitor

Cat.No.S2073

Mitiglinide Calcium (KAD-1229) is a blood glucose-lowering drugs, stimulating insulin secretion by closing the ATP-sensitive K+ channels in pancreatic beta-cells.
Mitiglinide Calcium Potassium Channel inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 668.88

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S207301 Ethanol]2 mg/mL]false]DMSO]Insoluble]false]Water]Insoluble]false Purity: 99.90%
99.90

Chemical Information, Storage & Stability

Molecular Weight 668.88 Formula

(C19H24NO3)2.Ca

 Storage (From the date of receipt)
CAS No. 207844-01-7, 145525-41-3 Download SDF Storage of Stock Solutions

Synonyms KAD-1229 Smiles C1CCC2CN(CC2C1)C(=O)CC(CC3=CC=CC=C3)C(=O)[O-].C1CCC2CN(CC2C1)C(=O)CC(CC3=CC=CC=C3)C(=O)[O-].[Ca+2]

Solubility

In vitro
Batch:

Ethanol : 2 mg/mL

DMSO : Insoluble ( Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
Potassium channel [1]

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04349696 Completed
Type 2 Diabetes Mellitus|Liver Dysfunction
Orient Europharma Co. Ltd.
 February 11 2014 Phase 4
NCT01403818 Completed
Healthy|Pharmacokinetics of ASP1941|Pharmacokinetics of Mitiglinide
Astellas Pharma Inc
 June 2011 Phase 1
NCT00566865 Completed
Type 2 Diabetes Mellitus
Elixir Pharmaceuticals
 November 2007 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map